The firm will conduct a Phase I trial of its KRAS G12D inhibitor in solid tumors and a Phase II trial of its G12C inhibitor plus an ERK1/2 inhibitor in NSCLC.
The proceeds may in part fund R&D of its product candidates, which include the pan-RAS molecular glue ERAS-0015 and the KRAS inhibitor ERAS-4001.
Otsuka Pharmaceutical, which licensed the antisense oligonucleotide from Ionis, has rights to commercialize it in Europe and Asia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback